Curcumin can sensitize cancer cells to gefitinib therapy in NSCLC with different EGFR status through accelerating EGFR ubiquitination; also, curcumin can attenuate gefitinib-induced gastrointestinal adverse effects via altering p38 activation and reducing cell apoptosis in intestinal epithelial cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.